Dyne Therapeutics (NASDAQ:DYN) Shares Up 3.9%

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares traded up 3.9% during trading on Thursday . The company traded as high as $35.30 and last traded at $35.25. 132,541 shares were traded during trading, a decline of 92% from the average session volume of 1,718,124 shares. The stock had previously closed at $33.92.

Analyst Ratings Changes

Several research firms have recently weighed in on DYN. HC Wainwright upped their price target on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the stock a "buy" rating in a report on Monday, May 20th. Piper Sandler lifted their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, March 6th. Oppenheimer reissued an "outperform" rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research note on Monday, May 6th. Chardan Capital upped their target price on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, May 21st. Finally, Jefferies Financial Group upped their price objective on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a "buy" rating in a report on Monday, May 20th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.78.

Dyne Therapeutics Stock Up 4.4 %

The stock has a market cap of $3.09 billion, a P/E ratio of -8.74 and a beta of 1.06. The company has a 50-day simple moving average of $29.56 and a two-hundred day simple moving average of $24.26.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, meeting analysts' consensus estimates of ($0.81). As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, COO Susanna Gatti High sold 10,163 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the transaction, the chief operating officer now directly owns 148,792 shares of the company's stock, valued at $5,256,821.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Oxana Beskrovnaya sold 30,426 shares of the firm's stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $32.96, for a total transaction of $1,002,840.96. Following the completion of the transaction, the insider now owns 149,647 shares of the company's stock, valued at approximately $4,932,365.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Susanna Gatti High sold 10,163 shares of the business's stock in a transaction on Monday, June 24th. The stock was sold at an average price of $35.33, for a total value of $359,058.79. Following the completion of the sale, the chief operating officer now directly owns 148,792 shares in the company, valued at $5,256,821.36. The disclosure for this sale can be found here. Insiders sold 202,133 shares of company stock valued at $6,500,387 in the last 90 days. Insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently modified their holdings of the stock. Fcpm Iii Services B.V. purchased a new position in Dyne Therapeutics in the fourth quarter worth about $81,543,000. RA Capital Management L.P. purchased a new stake in Dyne Therapeutics in the first quarter worth approximately $140,666,000. Janus Henderson Group PLC grew its position in Dyne Therapeutics by 23,512.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company's stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in Dyne Therapeutics during the 4th quarter valued at $15,758,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Dyne Therapeutics by 8,284.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company's stock valued at $32,141,000 after buying an additional 1,118,590 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.